TP53 status and response to treatment in breast cancers

64Citations
Citations of this article
149Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The p53 wild-type protein plays an important role in cells as is shown by its fine regulation at different levels. Since its discovery, numerous mutations have been described. In breast cancers, p53 is mutated in almost 30 of cases, with a higher frequency in some tumor subtypes. TP53 mutation is reported to be a factor for good prognosis in some studies, while in others it is a factor for poor prognosis. The explanation for these different results could be linked to the fact that the studies were performed on different tumor types and with different therapy regimens. Copyright © 2011 Mariana Varna et al.

Cite

CITATION STYLE

APA

Varna, M., Bousquet, G., Plassa, L. F., Bertheau, P., & Janin, A. (2011). TP53 status and response to treatment in breast cancers. Journal of Biomedicine and Biotechnology. https://doi.org/10.1155/2011/284584

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free